

## DAFTAR PUSTAKA

1. Global Burden of Cancer (GLOBOCAN). 2020: New Global Cancer Data. UICC. (diakses 3 Maret 2022). Tersedia dari: <https://www.uicc.org/news/globocan-2020-new-global-cancer-data>
2. Global Burden of Cancer (GLOBOCAN). International Agency of Research on Cancer. 2020;1–2 p. (diakses 3 Maret 2022). Tersedia dari: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
3. Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. *J Cancer*. 2017;8(16):3131–41.
4. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, *et al*. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol*. 2013;31(31):3997–4013.
5. Lee KL, Kuo YC, Ho YS, Huang YH. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. *Cancers (Basel)*. 2019;11(9).
6. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, *et al*. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. *Breast Cancer Res Treat*. 2017;161(2):279–87.
7. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. *Curr Oncol [Internet]*. 2018;25(Suppl 1):S142–50.
8. Nedeljković M, Damjanović A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. *Cells*. 2019;8(9).
9. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). *Transl Androl Urol*. 2015;4(3):36580–380.
10. Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. *Neoplasia*. 2020;22.
11. A Great Cell Line for Prostate Cancer Research. (diakses 3 Maret 2022). Tersedia dari: <https://www.neuromics.com/a-great-cell-line-for-prostate-cancer-research>

12. Hossein G, Zavareh VA, Fard PS. Combined Treatment of Androgen-Independent Prostate Cancer Cell Line DU145 with Chemotherapeutic Agents and Lithium Chloride: Effect on Growth Arrest and/or Apoptosis. *Avicenna J Med Biotechnol.* 2012;4(2):75.
13. Yeong CH, Cheng M hua, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. *J Zhejiang Univ Sci B.* 2014;15(10):845–63.
14. Micali S, Bulotta S, Puppini C, Territo A, Navarra M, Bianchi G, *et al.* Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. *BMC Cancer.* 2014;14(1).
15. Renier C, Vogel H, Offor O, Yao C, Wapnir I. Breast cancer brain metastases express the sodium iodide symporter. *J Neurooncol.* 2010;96(3):331–6.
16. Damle AA, Narkar AA, Badwe RA. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma. *Indian J Exp Biol.* 2011 Jun;49(6):416–22.
17. Liu S, Liu H, Sun H, Deng S, Yue L, Weng Z, *et al.* (cRGD)<sub>2</sub> peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131. *Anticancer Drugs.* 2022;33(1):19–29.
18. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, *et al.* Expression of the sodium/iodide symporter in human prostate adenocarcinoma. *Urology.* 2010;75(4):773–8.
19. Ahmed KA, Davis BJ, Wilson TM, Wiseman GA, Federspiel MJ, Morris JC. Progress in gene therapy for prostate cancer. *Front Oncol.* 2012;2.
20. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A Steep Radioiodine Dose Response Scalable to Humans in Sodium Iodide Symporter (NIS) Mediated Radiovirotherapy for Prostate Cancer. *Cancer Gene Ther.* 2012;19(12):839.
21. Siege B. From radioelements to scientific applications. *Commiss à l'Énergie At aux Energies Altern.* 2005. (diakses 20 April 2022). Tersedia dari: <https://www.cea.fr/english/Documents/thematicpublications/radioactivity.pdf>
22. Zhao LM, Pang AX. Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF- $\kappa$ B pathways. *Brazilian J Med Biol Res.* 2017;50(1).

23. Adan A, Kiraz Y, Baran Y. Cell Proliferation and Cytotoxicity Assays. *Curr Pharm Biotechnol*. 2016 Aug 15;17(14):1213–21.
24. Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the MTT Assay. *Cold Spring Harb Protoc*. 2018;2018(6):469–71.
25. Oweida A. The Clonogenic Assay. *Mol Clin Radiobiol Work*. 2015;1(1):1–23.
26. Keratinocytes. ATCC. (diakses 31 Maret 2023). Tersedia dari: <https://www.atcc.org/cell-products/primary-cells/keratinocytes#t=productTab&numberOfResults=24>
27. López-García J, Lehocký M, Humpolíček P, Sába P. HaCaT Keratinocytes Response on Antimicrobial Atelocollagen Substrates: Extent of Cytotoxicity, Cell Viability and Proliferation. *J Funct Biomater*. 2014;5(2):43.
28. Ahad F, Ganie SA. Iodine, Iodine metabolism and Iodine deficiency disorders revisited. *Indian J Endocrinol Metab*. 2010;14(1):13.
29. Mathew P, Rawla P. Hyperthyroidism. *StatPearls*. 2021. (diakses 20 Mei 2022). Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK537053/>
30. Milanesi A, Brent GA. Iodine and Thyroid Hormone Synthesis, Metabolism, and Action. *Mol Genet Nutr Asp Major Trace Miner*. 2017;143–50.
31. Aceves C, Anguiano B, Delgado G. The Extrathyronine Actions of Iodine as Antioxidant, Apoptotic, and Differentiation Factor in Various Tissues. *Thyroid*. 2013;23(8):938.
32. Wapnir IL, Van De Rijn DM, Nowels K, Amenta PS, Walton K, Montgomery K, *et al*. Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections. *J Clin Endocrinol Metab*. 2003;88(4):1880–8.
33. Semba RD, Delange F. Iodine in human milk: Perspectives for infant health. *Nutr Rev*. 2001;59(8 I):269–78.
34. Poole VL, McCabe CJ. Iodide transport and breast cancer. *J Endocrinol*. 2015;227(1):R1–12.
35. De La Vieja A, Santisteban P. Role of iodide metabolism in physiology and cancer. *Endocr Relat Cancer*. 2018;25(4):R225–45.
36. Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and

antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. *Prostate*. 2013 Jan;73(1):31–41.

37. Aceves C, Anguiano B. Is Iodine an Antioxidant and Antiproliferative Agent for the Mammary and Prostate Glands?. *Comprehensive Handbook of Iodine*. Elsevier Inc. 2009;249–257 p.
38. Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. *Prostate*. 2013;73(1):31–41.
39. Dasar Radionuklida: Yodium. EPA AS. (diakses 6 September 2022). Tersedia dari: <https://www.epa.gov/radiation/radionuclide-basics-iodine>
40. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis - PubMed. *Nucl Med Rev Cent East Eur*. 2012;15(2):120–3.
41. Saha GB. Physics and radiobiology of nuclear medicine. *Phys Radiobiol Nucl Med*. 2013 Jan 1;1–356.
42. Elliyanti A, Susilo VY, Setiyowati S, Rao PV. An iodine treatments effect on cell proliferation rates of breast cancer cell lines; in vitro study. *Open Access Maced J Med Sci*. 2020;8(B):1070.
43. De la Vieja A, Riesco-Eizaguirre G. Radio-Iodide Treatment: From Molecular Aspects to the Clinical View. *Cancers (Basel)*. 2021;13(5):1–21.
44. Watkins EJ. Overview of breast cancer. *J Am Acad Physician Assist*. 2019;32(10):13–7.
45. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res*. 2020;22(1):1–13.
46. Rashid NS, Hairr NS, Murray G, Olex AL, Leftwich TJ, Gribble JM, *et al*. Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer. *Transl Oncol*. 2021;14(12).
47. Lee KL, Kuo YC, Ho YS, Huang YH. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. *Cancers (Basel)*. 2019;11(9).
48. Singh DD, Yadav DK. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. *Biomedicines*. 2021;9(8).

49. Namekawa T, Ikeda K, Horie-Inoue K, Inoue S. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells. *Cells*. 2019;8(1).
50. Wu X, Gong S, Roy-Burman P, Lee P, Culig Z. Current mouse and cell models in prostate cancer research. *Endocr Relat Cancer*. 2013;20(4).
51. Gritsina G, Gao WQ, Yu J. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. *Asian J Androl*. 2019;21(3):215.
52. Novita E, Hamid ARAH, Tanurahardja B. Perbedaan Ekspresi Androgen Receptor (AR) pada Hiperplasia Prostat dan Adenokarsinoma Prostat Tipe Asinar. G. Balint, Antala B, Carty C, Mabieme J-MA, Amar IB, Kaplanova A, editors. *Maj Patol Indones*. 2019;343–54.
53. Wang Q, Yang CS, Ma ZX, Chen JC, Zheng JN, Sun XQ, *et al*. Inhibition of prostate cancer DU145 cell growth with small interfering RNA targeting the SATB1 gene. *Exp Ther Med*. 2018;15(3):3028–33.
54. Hormone Therapy for Prostate Cancer. (diakses 12 Juli 2022). Tersedia dari: <https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html>
55. Elliyanti A, Rusnita D, Afriani N, Susanto YDB, Susilo VY, Setiyowati S, *et al*. Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response. *Nucl Med Mol Imaging*. 2020;54(1):35.
56. Verma A. *Animal Tissue Culture: Principles and Applications*. *Anim Biotechnol Model Discov Transl*. 2014 Jan 1;211–31.
57. Kaur G, Dufour JM. Cell lines: Valuable tools or useless artifacts. *Spermatogenesis*. 2012;2(1):1.
58. MDA-MB-231. ATCC. (diakses 28 Mei 2022). Tersedia dari: <https://www.atcc.org/products/htb-26>
59. Control Q. MDA-MB-231 / GFP Cell Line. *Cell*. 2009;1–2.
60. Detailed Information JCRB1559. (diakses 30 November 2022). Tersedia dari: [https://cellbank.nibiohn.go.jp/~cellbank/cgi-bin/search\\_res\\_det.cgi?RNO=JCRB1559](https://cellbank.nibiohn.go.jp/~cellbank/cgi-bin/search_res_det.cgi?RNO=JCRB1559)
61. DU 145. ATCC. (diakses 28 Mei 2022). Tersedia dari: Available from: <https://www.atcc.org/products/htb-81>
62. DU145 Transfection Kit (Prostate Carcinoma Cells) Transfection Reagents

Cell Lines, In Vivo. Altogen Biosystems. (diakses 30 November 2022). Tersedia dari: <https://altogen.com/product/du145-transfection-reagent-prostate-carcinoma-cells/>

63. What is the morphology of DU145 cells?. Research Gate. (diakses 30 November 2022). Tersedia dari: [https://www.researchgate.net/post/what\\_is\\_the\\_morphology\\_of\\_DU145\\_cells](https://www.researchgate.net/post/what_is_the_morphology_of_DU145_cells)
64. Kang R, Zhao S, Liu L, Li F, Li E, Luo L, *et al.* Knockdown of PSCA induces EMT and decreases metastatic potentials of the human prostate cancer DU145 cells. *Cancer Cell Int.* 2016;16(1):1–12.
65. Vikas B, Anil S. Cell-Based Assays in Cancer Research. *Cell Growth.* 2019. (diakses 27 Mei 2022). Tersedia dari: [undefined/state.item.id](https://www.cellgrowth.com/undefined/state.item.id)
66. Sultan Aslantürk Ö. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages Provisional chapter In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages. 2018;1-18.
67. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, *et al.* Cell Viability Assays. *Assay Guid Man.* 2016. (diakses 14 Juli 2022). Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK144065/>
68. Rafehi H, Orłowski C, Georgiadis GT, Ververis K, El-Osta A, Karagiannis TC. Clonogenic Assay: Adherent Cells. *J Vis Exp.* 2011;(49):49.
69. Reinking L. *ImageJ Basics.* 2007. (diakses 1 desember 2022). Tersedia dari: <http://rsb.info.nih.gov/ij/>
70. Aykul S, Martinez-Hackert E. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. *Anal Biochem.* 2016;508:97.
71. Volpe DA, Hamed SS, Zhang LK. Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination. *AAPS J.* 2014;16(1):172.
72. Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, *et al.* Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various In Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. *Drug Metab Dispos.* 2013;41(7):1347–66.
73. How does GraphPad Prism compare with Microsoft Excel? FAQ 1246. GraphPad. (diakses 2 Juni 2023). Tersedia dari: <https://www.graphpad.com/support/faq/how-does-graphpad-prism->

compare-with-microsoft-excel/

74. Blois MS. Antioxidant determinations by the use of a stable free radical. *Nature*. 1958;181(4617):1199–200.
75. Elliyanti A, Salsabila D, Susilo VY, Setiyowati S, Endrinaldi E. Breast Cancer Cell Lines Viability on Radioactive Iodine Treatment. *World J Nucl Med*. 2022;21(01):A006.
76. Brito AF, Abrantes AM, Teixo R, Pires AS, Ribeiro AC, Ferreira RF, *et al*. Iodine-131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma. *Int J Oncol*. 2020;56(3):709–27.
77. Chen F, Yin S, Zhu J, Jia L, Zhang H, Yang C, *et al*. Effects of nuclear factor- $\kappa$ B on the uptake of <sup>131</sup>Iodine and apoptosis of thyroid carcinoma cells. *Mol Med Rep*. 2018;17(4):4959–64.
78. Kogai T, Brent GA. The Sodium Iodide Symporter (NIS): Regulation and Approaches to Targeting for Cancer Therapeutics.
79. Yao C, Pan Y, Li Y, Xu X, Lin Y, Wang W, *et al*. Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. *Oncol Rep*. 2015;34(1):59–66.
80. Darabi N, Keshavarz M, Nabipour I, Assadi M. The sodium iodide symporter (NIS) as theranostic gene: potential role in pre-clinical therapy of extra-thyroidal malignancies. *Clin Transl Imaging*. 2023;11(2):113–25.
81. Zhao Z, Huang R, Cai H, Liu B, Zeng Y, Kuang A. Improved radioiodine-131 imaging of prostatic carcinoma using the sodium iodide symporter gene under control of the survivin promoter. *Int J Clin Exp Pathol*. 2018;11(8):4067–72.
82. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. *Cancer Gene Ther*. 2012;19(12):839–44.
83. Spitzweg C, Nelson PJ, Wagner E, Bartenstein P, Weber WA, Schwaiger M, *et al*. The sodium iodide symporter (NIS): Novel applications for radionuclide imaging and treatment. *Endocr Relat Cancer*. 2021;28(10):T193–213.
84. Aceves C, Mendieta I, Anguiano B, Delgado-González E. Molecular Iodine Has Extrathyroidal Effects as an Antioxidant, Differentiator, and Immunomodulator. *Int J Mol Sci*. 2021;22(3):1–15.